Palbociclib (brand name Ibrance) was the first CDK 4/6 inhibitor approved by the FDA to treat breast cancer. In combination, ...

Thanks to the new FDA policy, Ibrance has become the first and only CDK 4/6 inhibitor to be given the nod in the US for first-line treatment of men with HR+, HER2- metastatic breast cancer ...

NICE has rejected Pfizer’s Ibrance breast cancer drug in first draft guidance, citing the treatment's high cost. The decision confirms the company’s fears that the drug would fare badly under ...

Among the many promising advances in breast cancer treatment in recent years are ... affect the CDK4 protein more than the CDK6 protein. Ibrance and Kisqali affect both CDK4 and CDK6 and have ...

When you have HER2-negative advanced (metastatic) breast cancer, treatment usually focuses on ... like abemaciclib (Verzenio), palpociclib (Ibrance), and ribociclib (Kisqali).

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

March 11 (Reuters) - Pfizer (PFE.N), opens new tab and Arvinas' (ARVN.O), opens new tab experimental treatment failed to delay progression of breast cancer in patients with most common type of the ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

The Breast Cancer market is undergoing significant expansion, driven by increasing disease prevalence and the introduction of innovative therapeutic options from companies such as ...